# A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation

> **NCT03995901** · PHASE3 · TERMINATED · sponsor: **Talaris Therapeutics Inc.** · enrollment: 15 (actual)

## Conditions studied

- Transplanted Organ Rejection

## Interventions

- **BIOLOGICAL:** FCR001

## Key facts

- **NCT ID:** NCT03995901
- **Lead sponsor:** Talaris Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-25
- **Primary completion:** 2023-02-16
- **Final completion:** 2023-02-16
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Talaris decided to discontinue living donor kidney transplant development program
- **Last updated:** 2023-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03995901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03995901, "A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03995901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*